share_log

微創醫療：截至二零二三年十二月三十一日止年度之全年業績預告

MICROPORT: ESTIMATED ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 5 09:30
Summary by Moomoo AI
微創醫疗科學有限公司（「微創醫疗」）發布截至2023年12月31日止年度之全年業績預告，儘管面臨國內外不利因素，公司銷售收入實現同比增長超過15%。增長主要來自於旗下附屬公司，包括心脈醫療、微創腦科學、心通醫療及微創機器人的新產品推廣和市場份額提升。此外，集團內其他主要業務及新興業務也實現穩定及指數級增長。由於主要業務收入大幅增加，以及實施成本節約措施和提升運營效率，公司預計年度虧損不超過580.0百萬美元，較去年同期減少，剔除一次性及╱（或）非現金性撥備及損失後，年度虧損不超過436.0百萬美元，同比減虧超過13%。公司將繼續聚焦業務，提高收入，降低相關費用，致力於未來幾年大幅減虧並實現盈虧平衡。公司股份及證券持有人及潛在投資者應留意，目前公司仍在準備及完成2023年年度業績報告，並預計於2024年3月末前刊發。
微創醫疗科學有限公司（「微創醫疗」）發布截至2023年12月31日止年度之全年業績預告，儘管面臨國內外不利因素，公司銷售收入實現同比增長超過15%。增長主要來自於旗下附屬公司，包括心脈醫療、微創腦科學、心通醫療及微創機器人的新產品推廣和市場份額提升。此外，集團內其他主要業務及新興業務也實現穩定及指數級增長。由於主要業務收入大幅增加，以及實施成本節約措施和提升運營效率，公司預計年度虧損不超過580.0百萬美元，較去年同期減少，剔除一次性及╱（或）非現金性撥備及損失後，年度虧損不超過436.0百萬美元，同比減虧超過13%。公司將繼續聚焦業務，提高收入，降低相關費用，致力於未來幾年大幅減虧並實現盈虧平衡。公司股份及證券持有人及潛在投資者應留意，目前公司仍在準備及完成2023年年度業績報告，並預計於2024年3月末前刊發。
MICROCHUN MEDICAL SCIENCES CO., LTD. (“MICRO CHUNG MEDICAL”) RELEASED ITS ANNUAL RESULTS FORECAST FOR THE YEAR ENDED DECEMBER 31, 2023. DESPITE ADVERSE DOMESTIC AND FOREIGN FACTORS, THE COMPANY'S SALES REVENUE ACHIEVED A YEAR-OVER-YEAR GROWTH OF MORE THAN 15%. Growth mainly came from new product promotions and market share gains in subsidiaries including Cardiac Medicine, Micro Brain Sciences, Cardiac Medicine and Micro-Startup Robotics. In addition, the Group's other major businesses and emerging businesses also achieved stable and index-driven growth. Due to the significant increase in core business revenues, as well as the implementation of cost savings measures and improved operating efficiencies, the Company expects an annual loss of not more than $580.0 million, a decrease from the same period...Show More
MICROCHUN MEDICAL SCIENCES CO., LTD. (“MICRO CHUNG MEDICAL”) RELEASED ITS ANNUAL RESULTS FORECAST FOR THE YEAR ENDED DECEMBER 31, 2023. DESPITE ADVERSE DOMESTIC AND FOREIGN FACTORS, THE COMPANY'S SALES REVENUE ACHIEVED A YEAR-OVER-YEAR GROWTH OF MORE THAN 15%. Growth mainly came from new product promotions and market share gains in subsidiaries including Cardiac Medicine, Micro Brain Sciences, Cardiac Medicine and Micro-Startup Robotics. In addition, the Group's other major businesses and emerging businesses also achieved stable and index-driven growth. Due to the significant increase in core business revenues, as well as the implementation of cost savings measures and improved operating efficiencies, the Company expects an annual loss of not more than $580.0 million, a decrease from the same period last year, excluding one-time and/or non-cash provisions and losses, a year-over-year loss of less than $436.0 million, a year-over-year decrease A loss of more than 13%. The Company will continue to focus on the business, increase revenue, reduce related expenses, and strive to significantly reduce losses and achieve a balance of profit and loss in the coming years. Holders of shares and securities and potential investors should note that the Company is currently preparing and finalizing its 2023 results and is expected to be published by the end of March 2024.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more